Inve India ▾

Senores Pharmaceuticals share price & results

Senores Pharmaceuticals Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Ahmedabad-based formulation and API maker supplying regulated (US/Canada/UK), emerging-market and Indian hospital (branded generics) pharma channels.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue180 ₹ crore+30.4% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin30.0 %+5.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit30.0 ₹ crore+42.9% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity14.65 %+1.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-32.07 %+19.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)50.88 %−26.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

7 of 13 judged targets kept · 18 open · verdicts reflect calls analysed to Q1 FY27.

Senores Pharmaceuticals Limited management guidance track record on Inve: 31 targets tracked across analysed earnings calls (7 achieved, 6 missed, 18 open).

TargetOriginal wordingSaidLatest callVerdict
Apnar Pharma Revenue (FY27)INR 120 crores to INR 150 crores
Call transcript, Q3 FY26 · 20 Jan 2026		Q3 FY26Q1 FY27:The revised target of INR 80-100 crores for FY27 was not reiterated. Management discussed commercializing 6 products and producing 30 million units from the facility, but did not provide a revenue update against the guidance.
Call transcript, Q1 FY27 · 27 Jul 2026		Ghosted
Launch of 28 approved ANDAs28 ANDAs launched within next 6-8 quarters
Call transcript, Q3 FY26 · 20 Jan 2026		Q3 FY26Q1 FY27:The target was reframed to '35 ANDAs planned for commercialization over the next 18 to 20 months'. This represents a smaller number of products over a longer timeframe compared to the Q4 revised guidance.
Call transcript, Q1 FY27 · 27 Jul 2026		Delayed
FY26 Top line growth50% growth in top line for FY26 over FY25
Call transcript, Q1 FY26 · 24 Jul 2025		Q1 FY26Q4 FY26:FY26 revenue grew by 62% YoY to INR 664 crores, surpassing the 50% growth target.
Call transcript, Q4 FY26 · 14 May 2026		Achieved

Source: Inve Guidance Tracker for Senores Pharmaceuticals Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

6 of Senores Pharmaceuticals Limited's 31 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 28 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,245.5 +2.48% · +₹30.2

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +62.1% 1Y

₹0.8k₹1.0k₹1.2k₹1.4k₹1.6kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 20 Jan 2026Q4 FY26 — 14 May 2026Q1 FY27 — 27 Jul 2026

1Y: ₹768.45 on 24 Oct 2025 → ₹1,245.5. High ₹1,550.9 (19 Aug 2026), low ₹710.25 (23 Mar 2026).

Previous close
₹1,215.3
Market cap
₹5.7k Cr
52-week range
₹710.25 – ₹1,550.9
One year
+61.09%
Price to earnings (TTM to Jun 2026)
45.52×
Return on equity (TTM to Jun 2026)
14.65%

Overview

Symbol
NSE:SENORES
Exchange
NSE
Currency
INR

What Senores Pharmaceuticals Limited does

Based on the company's own presentations, annual report and earnings calls.

Senores Pharmaceuticals identifies, develops and manufactures specialty and complex generic pharmaceutical products, earning through long-term marketing/distribution tie-ups and profit-sharing in Regulated Markets (US, Canada, UK), direct product registrations across 40+ Emerging Markets, contract development and manufacturing (CDMO/CMO) for global pharma customers, and domestic supply of critical-care injectables and APIs. It owns manufacturing facilities in Atlanta (US) and Gujarat (India) spanning oral solids, injectables, oral liquids, ORS and APIs, and grows both organically (in-house ANDA filings) and via acquisitions/joint ventures (Apnar Pharma, Zoraya Pharmaceuticals, Amerisyn JV) that add regulated-market manufacturing and market access.

Segments

  • Regulated Markets
  • Emerging Markets
  • Branded Generics
  • API / Others
Manufacturing facilities
1 USFDA-approved facility in Atlanta, US; 2 formulation facilities in Gujarat, India (1 USFDA-approved); 2 API manufacturing facilities in Gujarat, India
Approved ANDAs (Regulated Markets)
51, covering 151 strengths
Commercialized ANDAs
21, covering 46 strengths
ANDAs under development pipeline
27, covering 66 strengths
Countries with marketed/registered products (Emerging Markets)
40+ countries
Emerging Markets product registrations / applications filed
478 product registrations; 904 applications filed
Founded 2017Headquarters Ahmedabad, Gujarat, India Company website

How the price took the results

close before → close after

Q1 FY27
+1.8%
27 Jul
Q4 FY26
−2.0%
14 May
Q3 FY26
−2.7%
20 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Senores Pharmaceuticals Limited

Free account: one company. Everything above stays public.

Write why you follow Senores Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Senores Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.